Posted by AGORACOM-JC
at 8:42 AM on Wednesday, January 20th, 2021
Company launches first-ever COVID-safe location-based (LBE) Virtual Reality attractions division “UNCONTAINED” to disrupt the marketplace and fulfill demand from its Family Entertainment Center (FEC) clients.
Immersive Tech is planning for a public listing in the first half of 2021.
Leading immersive experience company builds upon current and past relationships with major companies.
Announcement brings creation of the world’s first-ever free-roam interactive VR franchise attraction available for rapid sale to the global attraction and entertainment marketplace.
VANCOUVER, British Columbia, Jan. 20, 2021 — Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) , a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that its portfolio company Immersive Tech (“Company”) has launched a premiere new Location-Based Entertainment (LBE) VR attractions division named UNCONTAINED to capitalize on the growing demand for COVID-safe attractions. UNCONTAINED will be the world’s first free-roam interactive VR franchise attraction, built for a COVID world within shipping containers. The experience will allow for up to six players to roam freely within the container while interacting inside a digital environment as a team while making decisions that help guide and define the story.
Immersive Tech designs, engineers and builds custom technology-driven experiences, whether they facilitate brand integration or are aiming to create the best real life adventure possible. The Company recently announced the creation of three unique entertainment escape rooms custom designed and built for Apex Entertainment’s new location in Virginia Beach VA, USA. The three custom room themes include an underwater submarine adventure, a post-war bunker experience, and an AI-controlled warship gone rogue featuring a race against time and a family-friendly focus.
“UNCONTAINED” leverages the manner of design experience that Immersive Tech has gained and honed over the past four years in creating and launching highly successful interactive escape rooms for Family Entertainment Centers. This is complemented by a fundamental understanding of shipping containers as highlighted in their recent 3-room escape experience for Leaps by Bayer, a Bayer Pharmaceutical company, in 2020.
Tags: small cap, small cap stocks, stocks, telehealth, telemedicine, tsx Posted in Victory Square Technologies Inc. | Comments Off on Victory Square Technologies $VST.ca $VSQTF Portfolio Company, Immersive Tech, Announces the Creation of World’s First #COVID-safe Location-Based Entertainment (LBE) Virtual Reality #VR Division “UNCONTAINED” $DBO.ca $YDX.ca $SEV.ca $NTAR.ca
Posted by AGORACOM-JC
at 9:19 AM on Tuesday, January 19th, 2021
Hydreight provides a completely compliant turnkey business model for health professionals to offer fully licensed medical, health & wellness services through an on-demand and on-site platform.
In addition to providing telehealth services, Hydreight also provides a diverse suite of health & wellness protocols that include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments.
Hydreight is a USA certified e-script and telemedicine provider, allowing Hydreight to offer a wide array of health and medical services in all 50 states.
Hydreight provides full pharmaceutical offerings across the United States (Hydreight has full 503B Pharmaceutical supply capabilities ).
Hydreight has established key relationships and supply network chains with major vendors including: Medline, Mckesson, Allergan (Botox), Galderma and numerous pharmacies.
VANCOUVER, British Columbia, Jan. 19, 2021 — Victory Square Technologies Inc. (” Victory Square ” or the “ Company ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that it has signed a binding letter of intent (the “ LOI ”) dated January 13, 2021 in respect of the acquisition (the “ Acquisition ”) of all of the shares of IV Hydreight Inc. (“ Hydreight ”), a mobile health and wellness service provider operating in the United States.
Founded in 2018, Hydreight provides a unique, custom built, proprietary telemedicine service that allows users to book confidential health & wellness and/or medical services at their home, hotel, office or wherever they may need discreet assistance. The business model of Hydreight leverages decentralized healthcare to bring quality telehealth, medical, health and wellness services to the masses in an efficient, scalable and cost effective way.
Posted by AGORACOM-JC
at 8:01 AM on Monday, January 11th, 2021
Company has commenced providing COVID-19 testing for Air Canada’s front-line employees who interact with members of the travelling public.
The Company’s COVID testing arrangement with Air Canada is being done on an as-needed basis as Datametrex has been selected as one of the testing and travel partners of Air Canada as publicly disclosed by Air Canada in a tweet dated November 22, 2020.
Toronto, Ontario–(January 11, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to provide an update on its COVID-19 testing business and announce that the Company has commenced providing COVID-19 testing for Air Canada’s (“Air Canada”) front-line employees who interact with members of the travelling public. The Company’s COVID testing arrangement with Air Canada is being done on an as-needed basis as Datametrex has been selected as one of the testing and travel partners of Air Canada as publicly disclosed by Air Canada in a tweet dated November 22, 2020.
The PCR based COVID-19 testing to be arranged by the Company will be for Air Canada employees including, pilots, pilot trainees, and flight attendants.
“With many companies looking to keep employees safe and healthy and especially with flight crews requiring a negative COVID-19 test to fly, Datametrex is proud to be a solution partner with Air Canada to safely and with confidence keep its flight crews and customers alike protected. Datametrex has provided thousands of PCR based tests to companies and employees over the last seven months and believes that continued testing of the public is the gold standard to protecting everyone and containing the spread of the COVID-19 virus,” commented Marshall Gunter, Datametrex’s Chief Executive Officer.
Posted by AGORACOM-JC
at 7:49 AM on Thursday, January 7th, 2021
Announced today that it has entered into a binding Letter of Intent to acquire 100% of Concierge Medical Consultant Inc., an arm’s length private telehealth and medical concierge services company
Company believes that in the current pandemic environment that there is a likely increase in mental health issues in society attributed to periods of extended isolation and related the disruption of social interaction.
Accordingly, management of the Company feel that there is a significant need in the market place for provide personal health solutions and the Company recognizes telehealth and concierge medical service as a part of solution to this growing problem.
Toronto, Ontario–(January 7, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce today that it has entered into a binding Letter of Intent (the “LOI“) to acquire 100% of Concierge Medical Consultant Inc. (“Concierge“), an arm’s length private telehealth and medical concierge services company, incorporated under the laws of British Columbia (the “Transaction”).
Subject to the completion of satisfactory due diligence by both Datametrex and Concierge, under the terms and conditions of the LOI, Datametrex and Concierge will enter into a Definitive Agreement (the “Definitive Agreement“) on or about January 20, 2021.
The Company believes that in the current pandemic environment that there is a likely increase in mental health issues in society attributed to periods of extended isolation and related the disruption of social interaction. Accordingly, management of the Company feel that there is a significant need in the market place for provide personal health solutions and the Company recognizes telehealth and concierge medical service as a part of solution to this growing problem.
“We strongly believe that there is a growing need for remote health and wellness solutions as a result of the pandemic. The lockdowns and the isolation that Canadians have endured this past year have only increased the need for mental and physical health solutions. By providing Telehealth solutions we are able to keep people out of the already overwhelmed hospital infrastructure while at the same time providing Canadians with professional advice and care that they need and deserve.”, said Andrew Ryu, the Company’s Chairman.
Posted by AGORACOM-JC
at 8:13 PM on Monday, December 14th, 2020
Highlights:
MedX partners with national telehealth leader IVPG in the Netherlands
Two skin screening clinics opened in November 2020, with more than 800 assessments on close to 500 patients completed to date using MedX’s DermSecure ® platform
Three additional clinics to come online in the Netherlands by the end of December 2020
IVPG plans to expand to 41 skin assessment clinics by 2022
More than half of all cancers reported in the Netherlands are skin cancers
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, announces that it has begun the rollout of DermSecure ® , MedX’s skin screening telemedicine platform, across the Netherlands in partnership with national telehealth leader The Netherlands Institute for Prevention and Health (“IVPG”).
“Telehealth allows us to assess patients, relay test results and provide video consultations with IVPG doctors, ultimately offering greater access to medical specialists during the COVID-19 crisis,” commented Paul Vlaanderen, IVPG Founder & CEO. “This improved access to healthcare specialists has directly resulted in higher quality care and the ability for patients to play a greater role in their healthcare management. We opened two locations in November and experienced substantial interest in the skin screening service, completing over 800 assessments on nearly 500 patients so far, and the DermSecure platform worked flawlessly. We will add another three locations, Rotterdam, Utrecht and Den Haag, to our IVPG network in 2020. IVPG further plans to bring the total number of scanning centers to 41 by 2022.”
“According to the World Cancer Research Fund, the Netherlands is ranked fifth globally for melanoma skin cancer. We know that early detection of skin cancer results in lower mortality rates, lower health care costs and much better patient outcomes. MedX’s advanced imaging technology and secure, scalable, teledermatology platform was a perfect fit to address the need for rapid skin screening in the Netherlands,” continued Mr. Vlaanderen.
Naman Demaghlatrous, MedX’s Managing Director, Europe, Middle East and Africa, was very impressed with the results of the implementation, stating, “Building on our pilot project with IVPG, DermSecure ® provides the requisite security and scalability to open multiple centers and expand this partnership significantly. We are honoured to work with Mr. Vlaanderen as he has been a pioneer in championing telehealth in the Netherlands. We look forward to playing a crucial role in enhancing Netherlanders’ access to early screening and thereby reduce skin cancer deaths.”
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com
About IVPG
IVPG is a Netherlands based Institute for Prevention and Health using telehealth for the delivery of digital healthcare. We are a collaboration of doctors and specialists. Together we help the Dutch to live a healthy and energetic life. IVPG provides the Dutch people with health information, free preventive examinations and advice to give more in-depth insight into their health. Although we are not always in control of our health, we can often manage it. That is our commitment. www.ivpg.nl
Forward-Looking Statements
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Posted by AGORACOM-JC
at 8:20 AM on Monday, November 30th, 2020
Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019.
Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020.
Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period.
MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR ( www.sedar.com ).
The Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019. Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020. Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period. The Company reported a loss for the three months ended September 30, 2020 of $1,083,772 or $0.01 per share compared with a loss of $577,648, or $0.00 per share for the three months ended September 30, 2019.
The Company reported revenue of $337,885 for the nine months ended September 30, 2020, compared with revenue of $678,886 for the nine months ended September 30, 2019. Revenue from SIAscopy ® of $127,093 was 21% higher than in the first nine months of 2019. Revenue from the Company’s therapeutic laser line of $210,792 for the nine-month period was 63% lower than the $574,069 in the prior year period. The Company reported a loss for the nine months ended September 30, 2020 of $2,532,171 or $0.02 per share, compared with a loss of $2,086,892, or $0.01 per share for the nine months ended September 30, 2019.
“We are pleased that we had strong revenue growth in Q3 compared to Q2, as we more than doubled revenue in each of our product lines,” noted Rob von der Porten, Executive Chairman, and acting CEO. “We made our first shipment of SIAscopy ® units to our Brazilian distribution partner, where they will be deployed on our DermSecure ® platform over the coming months. The sales and marketing team are building a pipeline of international distribution partners for our SIAscopy ® on DermSecure ® telemedicine platform and are experiencing strong interest in the Company’s unique teledermatology platform. While COVID-19 will continue to have an impact on all businesses, it is increasing the interest in telemedicine in general, albeit it is impacting the rate of implementation. While our revenue increased over the second quarter, the loss for the quarter was higher as we built out our sales team, increased marketing efforts, and spent on continued enhancements to our DermSecure ® platform, and as well, we incurred non-cash share-based compensation expense. We remain convinced that we will have long-term, sustainable growth with the MedX DermSecure ® platform and that it is the ‘Gold Standard’ in the teledermatological market space.”
The Company also announces that 800,000 stock options have been granted to Directors. Such options have an exercise price of $0.17 per share, will expire on November 25, 2025, and vest immediately.
MedX also announces it has retained Venture North Capital Inc. (“Venture North”) for strategic marketing, investor relations and capital markets communications services. Venture North will arrange and attend meetings with professional investors, maintain ongoing contact and broaden relationships with the professional investment community on MedX’s behalf.
Under the terms of the agreement, MedX will pay Venture North a monthly fee of $6,000 for ongoing strategic services for an initial six (6) months, after which the relationship will continue on a monthly basis. The agreement may be terminated by MedX or Venture North on 60 days written notice. Venture North will also be granted stock options (the “Options”), totaling up to 900,000 common shares of the Company, which will vest and become exercisable quarterly with 225,000 of the options vesting on each of the dates that are three, six, nine and twelve months from the beginning of the Engagement Period. The Options will be exercisable at a price of $0.17 per share for a period of two years. The appointment and option grant are subject to TSX Venture Exchange approval.
Summary of Recent Announcements:
The following is a summary of recent announcements made by the Company, for which further details can be found under the Company’s profile at www.sedar.com .
MedX Announces Sales Agency Agreement with Ziemer Professional Corp.
On October 28, 2020, the Company announced it had completed a sales agency agreement with the Ziemer Professional Corporation. Ziemer will target its sales efforts within the medical, athletic, and pain management clinic markets. Six new clinics will begin installing the SIAscopy ® on Dermsecure ® telemedicine platform across Ontario and Saskatchewan.
MedX Adds Two New Members to Board of Directors
On October 15, 2020, the Company appointed Anthony Milonas and Wayne Cockburn as Directors of the Company. Mr. Milonas and Mr. Cockburn bring extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally. Mr. Milonas is President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Cockburn is President of The Clinic Network Canada, one of Canada’s largest providers of out-of-hospital pain management services.
MedX Expands Senior Leadership Team
On September 21, 2020, the Company announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), and Chantal Ward, RN, as Director, Dermatological Services. Mr. Demaghlatrous brings more than 20 years of experience in the healthcare industry, including roles with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Chantal Ward, RN, a Diploma Nurse Graduate with an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology.
MedX Announces Management Changes and Increased Focus on SIAscopy® on DermSecure®
On September 9, 2020, the Company announced management changes to enhance its focus on its dermatological services and products including DermSecure ® and SIAscopy ® . Mike Druhan, who has championed SIAscopy ® within the Company for a number of years, has been appointed President, Dermatological Services and Products. Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director, Light Therapy Products.
MedX Announces Closing of Non-Brokered Private Placement
On August 4, 2020, the Company announced that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at $0.12 per unit (“Unit”), to raise up to $2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of $312,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued will be restricted from trading for four months from the date of issue. In connection with this tranche of the private placement, cash commissions of $24,000 were paid.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com .
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:31 AM on Thursday, November 12th, 2020
Will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18.
NEW YORK, NY / November 12, 2020 / MedX Health Corp. (“MedX”, or the “Company”) (TSXV:MDX), a Company focused on becoming the leader in teledermatology, will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18. To register, or to schedule a virtual one-on-one meeting, visit https://investorsummitgroup.com/.
During the presentation, MedX’s CEO, Robert von der Porten, and Mike Druhan, President, Dermatology Products & Services, will provide an overview of the Company’s fully integrated telemedicine platform specializing in dermatology and how its platform is being deployed to revolutionize skin cancer detection methods.
The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.
ABOUT MEDX:
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
ABOUT THE INVESTOR SUMMIT:
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
Posted by AGORACOM-JC
at 5:30 PM on Wednesday, October 28th, 2020
Six new clinics installing SIAscopy™ on Dermsecure™ telemedicine platform in the next three weeks across Ontario and Saskatchewan
MedX enters into a sales agency agreement with specialty medical device distribution group Ziemer Professional Corp., targeting sales efforts within the medical, athletic, and pain management clinic markets
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX), the global leader in teledermatology, announces that it has completed a sales agency agreement with the Ziemer Professional Corporation. Mr. Paul Ziemer, President, has 20 years of experience in medical device sales and medical clinic operations. “I have been working with the MedX team to develop a go-to market strategy and I am pleased to announce that the first six clinics will roll-out in the next three weeks with installations across Ontario and Saskatchewan. Preparations are already in place for additional installations in Canada and the USA for December and early 2021,” stated Mr. Ziemer.
“COVID-19 has almost doubled the wait times in order to see a Dermatologist. MedX’s DermSecure™ teledermatology platform provides a perfect solution to this problem. I have received tremendous interest from my client base and expect rapid growth in both the USA and Canada,” Mr. Ziemer added.
“Mr. Ziemer’s enthusiasm and detailed knowledge of the economic drivers in the clinic market have been invaluable as we begin our roll-out strategy. Mr. Ziemer has a wide network and strong relationships with numerous medical clinics and practitioners. We believe he will develop a solid customer base in a number of key markets for MedX, and we look forward to supporting Mr. Ziemer and his team in their sales and marketing efforts,” commented Mr. Mike Druhan, President, Dermatological Products and Services.
About Ziemer Professional Corp.
Ziemer Professional Corporation has been partnering with health care innovators for over 20 years. We have a strong focus on delivering new and innovative medical technologies to medical/athletic clinics throughout North America and internationally. Areas of experience include Diabetic Wound Care, Peripheral Neuropathy, Biomechanical Gait and Posture Analysis, Telemedicine/Remote Patient Monitoring. ZPC provides sales support as well as educational leadership to its partners, patients and clinical customers. Improving patient access to preventative technologies is top of mind with a specific focus on delivering patient care to remote communities including a special relationship with First Nations.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com
Forward Looking Statements
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the Company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the Company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the Company as of the date hereof, and the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 4:22 PM on Thursday, October 15th, 2020
Announced that it has appointed Anthony Milonas and Wayne Cockburn as Directors of the Company, effective immediately.
Mr. Milonas and Mr. Cockburn have extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally.
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a Company focused on becoming the global leader in teledermatology, announces that it has appointed Anthony Milonas and Wayne Cockburn as Directors of the Company, effective immediately. Mr. Milonas and Mr. Cockburn have extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally.
Mr. Milonas is President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Milonas was responsible for the expansion of the group’s number of practices from 28 to approximately 55 and has held senior roles in both large publicly-traded companies as well as privately-held small and mid-sized companies. Mr. Milonas stated, “I am looking forward to working with such a talented team. MedX’s SIAscopy™ combined with its DermSecure™ platform are, in my view, an ideal combination for today’s challenging environment and the shift towards digital health care.”
Mr. Cockburn is President of The Clinic Network Canada, one of Canada’s largest providers of out-of-hospital pain management services. Mr. Cockburn previously founded the medical device company, iTech Medical, leading it through product approval in Europe and Canada. “I am very pleased to be joining the MedX team at such a pivotal time,” Mr. Cockburn said. “The meticulous development, regulatory and commercialization work that they’ve done over the past several years has, I believe, put them in a good position to not only become a leader in their field, but also allow them to save the lives of so many people who become affected by skin cancer.”
“We are delighted to add two executives of such notable experience to our Board,” noted Rob von der Porten, Chairman of MedX. “Anthony and Wayne have each held multiple leadership roles and have been integral in transforming smaller companies into strong organizations through the optimization of business strategies and operations, the pursuit of strategic partnerships and the building of brand channels. They both have a proven track record of bringing an operational focus in managing and growing healthcare companies and driving the profitable growth and expansion of businesses at national and international levels. Their insight will be invaluable as we build out the sales pipeline for our SIAscopy™ on Dermsecure™ telemedicine platform.”
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 2:36 PM on Friday, October 2nd, 2020
Announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa, effective immediately
Additionally, Chantal Ward, RN has taken a permanent position with the Company as Director, Dermatological Services.
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Additionally, Chantal Ward, RN has taken a permanent position with the Company as Director, Dermatological Services.
“Naman’s extensive background in healthcare and medical devices, along with his deep relationships will allow us to accelerate business development opportunities in the region,” said Mike Druhan, President of Dermatological Products & Services. “Chantal is an internationally recognized and respected leader in the dermatology and aesthetics spaces, bringing credibility to our offerings and putting an impressive opinion leader network at our disposal.”
Mr. Demaghlatrous has more than 20 years of experience in the healthcare industry, including roles with medical device and pharmaceutical companies leading business strategy, international product licensing, business development and operations. He has proven expertise in leading organizations through start-up to rapid growth, expansion and value creation with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Mr. Demaghlatrous will play an integral part in MedX’s revenue growth prospects by securing European, Middle Eastern and African partnerships for MedX’s skin assessment telemedicine technology. Initially supporting the roll out and expansions in the Netherlands, Spain and Turkey, he will also be responsible for securing joint ventures and partnerships across the EMEA Region.
“Helping patients access an e-consult on suspicious lesions or moles quickly and easily means better treatment and better outcomes,” noted Mr. Demaghlatrous. “There is already significant interest and traction across the region and I am expecting substantial growth over the next six to nine months.”
Chantal Ward RN, a Diploma Nurse Graduate from an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology. Her expertise is acknowledged across Canada and around the world, where she has provided guidance and training to hundreds of medical aesthetic professionals. Ms. Ward is Co-Founder of Clarity MedSpa & Laser Centre, Toronto and has significant experience with MedX’s SIAscopy on DermSecure™.
“I have been using this device in my clinic for several years and have caught multiple melanomas,” said Ms. Ward. “The device is easy to use and the ability to have a dermatologist provide a remote e-consult, within 72 hours, is critical. Early detection is the key to a successful patient outcome.”
“MedX is in full commercialization mode and Naman and Chantal are welcomed additions to our team. Recently, Damon Goodwin and Nick Hoffman have been announced to our senior management team and we are already feeling their impact. It is a satisfying to know that MedX can attract such seasoned professionals and I strongly believe that is because of the strength of our technology offering and the culture we have built,” further commented Mr. Druhan.
Currently, between two and three million non-melanoma skin cancers and 300,000 melanoma skin cancers occur globally each year. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation statistics, one in every five people will develop skin cancer in their lifetime. The global demand for SIAscopy on DermSecure™ will continue to increase with the growth of telemedicine and as early detection is recognized as the way to optimize survival and reduce healthcare costs.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Mike Druhan, President, Dermatological Services MedX Health Corp Tel: 905-599-7852
